Palatin Technologies to Join Russell Microcap Index
CRANBURY, N.J., June 27, 2014
CRANBURY, N.J., June 27, 2014 /PRNewswire/ --Palatin Technologies, Inc. (NYSE
MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific
peptide therapeutics for the treatment of diseases with significant unmet
medical need and commercial potential, announced that it is joining the
Russell Microcap® Index when Russell Investments reconstitutes its
comprehensive set of U.S. and global equity indexes later today. Palatin was
included on a preliminary list of additions posted on www.russell.com/indexes.
"We are pleased to be added to the Russell Microcap Index," said Carl Spana,
Ph.D., President and CEO of Palatin. "We believe being included in this index
will raise our profile within the investment community and provide us with the
opportunity to expand our shareholder base as we move into Phase 3 clinical
trials with bremelanotide for female sexual dysfunction later this year."
Membership in the Russell Microcap Index, which remains in place for one year,
means automatic inclusion in the appropriate growth and value style indexes.
Russell Investments, a global asset manager, determines membership for its
equity indexes primarily by objective, market-capitalization rankings and
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment strategies.
Approximately $5.2 trillion in assets are benchmarked to the Russell Indexes.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted,
receptor-specific peptide therapeutics for the treatment of diseases with
significant unmet medical need and commercial potential. Palatin's strategy is
to develop products and then form marketing collaborations with industry
leaders in order to maximize their commercial potential. For additional
information regarding Palatin, please visit Palatin's website at
Statements in this press release that are not historical facts, including
statements about future expectations of Palatin Technologies, Inc. such as
statements about listings on indexes, potential clinical trial results,
potential actions by regulatory agencies including the U.S. Food and Drug
Administration (FDA), regulatory plans, development programs, and market
potential for bremelanotide and other product candidates, are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995. Palatin intends that
such forward-looking statements be subject to the safe harbors created
thereby. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that could cause Palatin's actual results to
be materially different from its historical results or from any results
expressed or implied by such forward-looking statements. Palatin's actual
results may differ materially from those discussed in the forward-looking
statements for reasons including, but not limited to, results of nonclinical,
preclinical and toxicology studies, result of clinical trials, regulatory
actions by the FDA and the need for regulatory approvals,
Palatin's ability to fund development of its technology and establish and
successfully complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory approvals,
products developed by competing pharmaceutical, biopharmaceutical and
biotechnology companies, commercial acceptance of Palatin's products, and
other factors discussed in Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
CONTACT: Palatin Technologies Investor Inquiries:Stephen T. Wills, CPA, MST,
Chief Operating Officer / Chief Financial Officer, Tel: (609) 495-2200 /
email@example.com; Palatin Technologies Media Inquiries: Paul Arndt, MBA,
LifeSci Advisors, LLC, Managing Director, Tel: (646) 597-6992 /
SOURCE Palatin Technologies, Inc.
Press spacebar to pause and continue. Press esc to stop.